Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis.

Teresa CoelhoAaron YarlasMarcia Waddington-CruzMichelle K WhiteAsia Sikora KesslerAndrew LovleyMichael PollockSpencer GuthrieElizabeth J AckermannSteven G HughesChafic KaramSami KhellaMorie GertzGiampaolo MerliniLaura ObiciHartmut H SchmidtMichael PolydefkisP James B DyckThomas H Brannagan IiiIsabel ConceiçãoMerrill D BensonJohn L Berk

Published in: Journal of neurology (2019)

Patients with hATTR amyloidosis with polyneuropathy treated with inotersen showed preserved or improved QOL at 66 weeks compared to those who received placebo.

Keyphrases

multiple myeloma
double blind
wild type
study protocol